Crossref
Early response to incretin-based obesity pharmacotherapy
Trends in Endocrinology & Metabolism · 2026-11
DOI: 10.1016/j.tem.2026.10.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Endocrinology & Metabolism, 2026-11. Verfasst von Dimitrios Patoulias und 1 weiteren Autor:innen. Beteiligte Einrichtung: Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessalonik…. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
GLP-1glucose-dependent insulinotropic polypeptideincretinobesitytreatment response
Autor:innen und Institutionen
- Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. Electronic address: patoulias@auth.gr.
- Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, Rome, Italy; Obesity and Obesity-Related Cardiometabolic Complications Research Unit, IRCCS MultiMedica, Milan, Italy.
Zitieren
APA
Patoulias, D., & Conte, C. (2026). Early response to incretin-based obesity pharmacotherapy. Trends in Endocrinology & Metabolism. https://doi.org/10.1016/j.tem.2026.10.011
Vancouver
Patoulias D, Conte C. Early response to incretin-based obesity pharmacotherapy. Trends in Endocrinology & Metabolism. 2026. doi:10.1016/j.tem.2026.10.011
BibTeX
@article{Patoulias2026,
author = {Patoulias, Dimitrios and Conte, Caterina},
title = {Early response to incretin-based obesity pharmacotherapy},
journal = {Trends in Endocrinology & Metabolism},
year = {2026},
doi = {10.1016/j.tem.2026.10.011}
}
EUVIMED